• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).

作者信息

Spira Alexander, Cho Byoung Chul, Felip Enriqueta, Garon Edward B, Goto Koichi, Johnson Melissa, Leighl Natasha, Passaro Antonio, Planchard David, Popat Sanjay, Yang James Chih-Hsin, Lu Xiaoqian, Jiang Yong, Huang Jack, Lam Morgan, Kowanetz Marcin, Wang Shirley, Le John, Hsu Jerry Y, Zhou Cai-Cun

机构信息

Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, United States.

Division of Medical Oncology, Yonsei Cancer Center, Yonsei University of Medicine, Seoul, Republic of Korea.

出版信息

Lung Cancer. 2025 Jan;199:108066. doi: 10.1016/j.lungcan.2024.108066. Epub 2024 Dec 28.

DOI:10.1016/j.lungcan.2024.108066
PMID:39764938
Abstract
摘要

相似文献

1
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).FURVENT：伏美替尼与化疗作为一线治疗EGFR外显子20插入突变的晚期非小细胞肺癌的3期试验（FURMO-004）。
Lung Cancer. 2025 Jan;199:108066. doi: 10.1016/j.lungcan.2024.108066. Epub 2024 Dec 28.
2
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.一项评估 furmonertinib 治疗 EGFR 外显子 20 插入突变非小细胞肺癌患者的疗效和安全性的真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7729-7742. doi: 10.1007/s00432-023-04726-x. Epub 2023 Apr 1.
3
REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with exon 20 insertion-mutated NSCLC.REZILIENT3：一线使用齐帕替尼联合化疗治疗20号外显子插入突变非小细胞肺癌患者的随机III期研究
Future Oncol. 2025 Feb;21(5):549-556. doi: 10.1080/14796694.2025.2457294. Epub 2025 Feb 16.
4
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.首例报告：厄洛替尼治疗 EGFR 外显子 20 插入突变阳性晚期肺腺癌患者的疗效：两项病例报告和文献复习
Medicine (Baltimore). 2023 Dec 29;102(52):e36667. doi: 10.1097/MD.0000000000036667.
5
Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with exon 20 insertion mutations.中国非小细胞肺癌伴外显子20插入突变的真实世界临床治疗结果
Front Oncol. 2022 Sep 2;12:949304. doi: 10.3389/fonc.2022.949304. eCollection 2022.
6
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.一线免疫治疗或血管生成抑制剂联合化疗治疗 EGFR 外显子 20 插入的晚期非小细胞肺癌：来自中国的真实世界证据。
Cancer Med. 2023 Jan;12(1):335-344. doi: 10.1002/cam4.4852. Epub 2022 May 24.
7
High-dose furmonertinib combined with intraventricular chemotherapy as salvage therapy for leptomeningeal metastasis from EGFR exon 20 insertion-mutated lung cancer.高剂量呋罗替尼联合脑室内化疗治疗 EGFR 外显子 20 插入突变型肺癌脑膜转移的挽救治疗。
J Neurooncol. 2024 Aug;169(1):203-213. doi: 10.1007/s11060-024-04716-0. Epub 2024 Jun 25.
8
Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI.伏美替尼用于表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌：EGFR酪氨酸激酶抑制剂（EGFR-TKI）中的一颗璞玉。
Front Pharmacol. 2024 Feb 19;15:1357913. doi: 10.3389/fphar.2024.1357913. eCollection 2024.
9
EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.中国晚期非小细胞肺癌患者的表皮生长因子受体第20外显子插入突变：全国性真实世界研究的分子异质性与治疗结果
Lung Cancer. 2020 Jul;145:186-194. doi: 10.1016/j.lungcan.2020.03.014. Epub 2020 Mar 18.
10
EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.非小细胞肺癌中 EGFR 外显子 20 插入与铂类化疗的反应。
Clin Lung Cancer. 2022 Mar;23(2):e148-e153. doi: 10.1016/j.cllc.2021.07.001. Epub 2021 Jul 19.

引用本文的文献

1
Advancing Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion-Mutated Non-small Cell Lung Cancer (NSCLC) Management Through Molecular Diagnostics and Targeted Therapies.通过分子诊断和靶向治疗推进表皮生长因子受体（EGFR）外显子20插入突变的非小细胞肺癌（NSCLC）的管理
Cureus. 2025 Apr 19;17(4):e82573. doi: 10.7759/cureus.82573. eCollection 2025 Apr.
2
New advances in the treatment of EGFR exon20ins mutant advanced NSCLC.表皮生长因子受体第20外显子插入突变的晚期非小细胞肺癌治疗新进展
Am J Cancer Res. 2025 Apr 25;15(4):1852-1873. doi: 10.62347/WTMU5537. eCollection 2025.
3
Efficacy and safety of furmonertinib in patients with EGFR‑mutant advanced lung adenocarcinoma after failure of multiple lines of therapy: A single‑center retrospective study.
伏美替尼在多线治疗失败的EGFR突变型晚期肺腺癌患者中的疗效和安全性：一项单中心回顾性研究
Oncol Lett. 2025 May 2;30(1):328. doi: 10.3892/ol.2025.15074. eCollection 2025 Jul.